MedPath

A randomized comparison of one controlled ovarian stimulation with corifollitropin alfa (CFA) versus up to three modified natural cycles (MNC) in expected and established poor responders

Phase 1
Recruiting
Conditions
Subfertility
Therapeutic area: Phenomena and Processes [G] - Reproductive and Urinary Physiological Phenomena [G08]
Registration Number
CTIS2023-509094-23-00
Lead Sponsor
niversitair Ziekenhuis Gent
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
300
Inclusion Criteria

women with a clinical indication for ART with an expected low response to ovarian stimulation. Expected low prognosis will be defined according to the POSEIDON classification, which stratifies patients according to whether they have an unexpected (groups 1 and 2) or expected (groups 3 or 4) inappropriate ovarian response to gonadotropin stimulation. This trial only includes patients fulfilling the criteria of groups 3 or 4: • POSEIDON Group 3: patients < 35 years with poor ovarian reserve pre-stimulation parameters (AFC < 5 or AMH < 1.2 ng/ml*) • POSEIDON Group 4: patients = 35 years with poor ovarian reserve pre-stimulation parameters (AFC < 5 or AMH < 1.2 ng/ml*) * AMH value should not be older than 12 months., Informed consent form (ICF) dated and signed, Age = 18 and < 45 years old, Body Mass Index (BMI) = 18.5 kg/m² and < 35 kg/m², Regular menstrual cycles (between 21 and 35 days), Two ovaries present, Current pregnancy-wish, Single embryo transfer (SET)

Exclusion Criteria

Basal FSH > 20 IU/L in the last 12 months, Simultaneous participation in another clinical study, Untreated and uncontrolled thyroid dysfunction, Tumors of the ovary, breast, uterus, pituitary or hypothalamus, Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause, Malformations of the reproductive organs, Current use of oral contraceptives, anti-psychotics, anti-epileptics or chemotherapy, Previous antibiotic hypersensitivity reactions (streptomycin and/or neomycin), Patients who undergo preimplantation genetic testing (PGT), fertility preservation or oocyte donation

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath